Changes in Beneficial Ownership · 4
Structure Therapeutics Inc.
Changes in Beneficial Ownership
Structured filing — 4
form4-06182026_050609.xml
Filing details
- Report period
- 2026-06-17
- Issuer
- Structure Therapeutics Inc.
- Issuer CIK
- 0001888886
- Trading symbol
- GPCR
Reporting owner 1
- Name
- Waldstreicher Joanne
- Reporting owner CIK
- 0001962413
- Relationship
- Director
- Address
- C/O STRUCTURE THERAPEUTICS INC., 601 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (right to buy) | 15[F1] | 2026-06-17 | A · Form 4 | 39,453 | A | 0 | [F2] | 2036-06-16 | Ordinary Shares | 39,453[F3] | 39,453 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").↩ 1
- F2
- The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,↩ 1
- F3
- The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.↩ 1
Signature 1
- Signed
- /s/ Jun Yoon, Attorney-in-Fact
- Date
- 2026-06-18
Company context
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.